Aclaris Therapeutics, Inc. (ACRS)
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.8M
- Net income
- -$64.9M
- Total assets
- $160.5M
- Market cap
- $608.9M
- Gross margin
- 73.3%
- Operating margin
- -975.9%
- Net margin
- -829.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.8M
- Cost of revenue
- $2.1M
- Gross profit
- $5.7M
- Operating expenses
- $82.1M
- Operating income
- -$76.4M
- Net income
- -$64.9M
- EPS (basic)
- $-0.53
- EPS (diluted)
- $-0.53
Balance sheet
- Total assets
- $160.5M
- Current assets
- $96.3M
- Total liabilities
- $57.4M
- Current liabilities
- $28.6M
- Shareholders’ equity
- $103.1M
Cash flow
- Operating cash flow
- -$47.1M
- Investing cash flow
- $48.4M
- Financing cash flow
- -$5.9M
- Net cash flow
- -$4.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $608.9M
- EPS (diluted)
- $-0.53
- Shares outstanding
- 116.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 7, 2015
Aclaris Therapeutics, Inc. (ACRS) Stock Price
- Reported a net loss of $64.9M in FY2025.
- Revenue grew 16% from FY2021 to FY2025.
- Gross margin of 73.3%, net margin -829.6%.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aclaris Therapeutics, Inc..
Write a review
News about Aclaris Therapeutics, Inc.
News & sentiment via Polygon.io
Aclaris Therapeutics, Inc.: frequently asked questions
Is Aclaris Therapeutics, Inc. an American company?
Aclaris Therapeutics, Inc. is a US-based company headquartered in Wayne, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aclaris Therapeutics, Inc. headquartered?
Aclaris Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, United States.
Is Aclaris Therapeutics, Inc. publicly traded?
Yes — Aclaris Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ACRS on the NASDAQ.
What does Aclaris Therapeutics, Inc. do?
Aclaris Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
